Switzerland· 69599002
Briumvi
A ublituximab product containing ublituximabum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Ublituximab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AG14 (ublituximab), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 8 of them publish a price we can compare per daily dose
Ublituximab · ATC L04AG14
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- ublituximabum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L04AG14
- ATC class
- Ublituximab
- Defined daily dose
- 2.68 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin76806959900273 Durchstf 6 mlCHF 6792.2
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ublituximab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBRIUMVINeuraxpharm Pharmaceuticals, S.L., Barcelona
- SpainBRIUMVI 150 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONNeuraxpharm Pharmaceuticals S.L.
- FinlandBriumviNeuraxpharm Pharmaceuticals S.L.
- United KingdomBriumvi 150mg/6ml concentrate for solution for infusion vialsNeuraxpharm UK Ltd
- IrelandBriumvi 150 mg Concentrate for solution for infusionNeuraxpharm Pharmaceuticals S.L.
- IcelandBriumviNeuraxpharm Pharmaceuticals S.L.
- NetherlandsBriumvi 150 mg concentraat voor oplossing voor infusieNeuraxpharm Pharmaceuticals S.L.
- NorwayBriumviNeuraxpharm Pharmaceuticals, S.L.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Briumvi
- Liechtenstein · Briumvi
- Norway · Briumvi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b90380f2-0e12-4357-8f41-639ceaad4e29 GET /v1/drugs/b90380f2-0e12-4357-8f41-639ceaad4e29?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "ublituximabum 150 mg",
"valid_from": "2025-07-01",
"limitations": "[{\"description\":\"BRIUMVI wird vergütet für die Behandlung von erwachsenen Patienten mit schubförmiger Multipler Sklerose (RMS) mit aktiver Erkrankung, definiert durch klinischen Befund oder Bildgebung.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21891.01\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2025-07-01\",\"validTo\":null}]",
"galenic_form": "Inf Konz 150 mg/6ml",
"therapeutic_area": null,
"sl_inclusion_date": "2025-07-01",
"self_retention_pct": 10
}See everything about ublituximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.